

Importance of applying treatment data to ascertain type 1 diabetes cases in health registries

Mitra Mosslemi , Nathan D Wong

To cite: Mosslemi M, Wong ND. Importance of applying treatment data to ascertain type 1 diabetes cases in health registries. *BMJ Open Diab Res Care* 2021;9:e002280. doi:10.1136/bmjdr-2021-002280

Received 17 March 2021
Accepted 2 April 2021

We read with great interest the article by Casagrande and colleagues concerning the comparison of the survey-based algorithms to ascertain type 1 diabetes (T1D) in the National Health and Nutrition Examination Survey (NHANES) and the National Health Interview Survey (NHIS).¹ Emphasizing the recent updates about the distribution of age at T1D onset is a great point in their work; however, an evidence-based comparison between the algorithms' accuracy would have been useful to the reader.

We had previously developed a treatment-based algorithm for identifying diabetes type in the NHANES after evaluating the magnitude of misclassification for each of the potential criteria for the classification from the epidemiologic evidence.² We excluded age at the diabetes diagnosis criterion because of its high rate of misclassification in the ascertainment of T1D.^{3,4} Instead, we used 'No use of oral hypoglycemic medication', 'Current insulin use', and 'Started taking insulin within a year after the diagnosis' criteria.² We agree with Casagrande *et al* that 'No use of oral hypoglycemic medication' alone is not enough for excluding type 2 diabetes (T2D) cases from the T1D ascertainment. Still, we disagree that the small percentages of use of oral hypoglycemic agents (2.4%–5%) among patients with T1D make the criterion improper for inclusion in a T1D ascertainment algorithm, as implied by the authors as the main weakness for algorithm 7, which used diabetes diagnosis at age <30 years, current insulin use, and not using oral hypoglycemics criteria.¹ Of note, none of the oral hypoglycemic medications have the Food and Drug Administration approval for use in people with T1D.⁵ Consequently, the T1D Exchange report of 5% of their patients with T1D taking oral non-insulin medications should be an upper bound compared with the national level since the T1D Exchange cohort comprises patients

from diabetes clinics and with better access to care than the national level.⁶

Our algorithm may underestimate the prevalence of T1D by excluding less than 5% of patients with T1D who took oral hypoglycemic medications. It instead minimizes misclassification of patients with T2D who took insulin (~15% to 25% of T2D)⁷ as T1D, which is crucial considering that 90%–95% of diabetes cases are T2D.⁸ The American Diabetes Association guidelines recommend metformin as the first-line treatment for patients with T2D, which indicates that early use of insulin in patients with T2D would be an adjunct to metformin, not as monotherapy.⁹ Therefore, 'No use of oral hypoglycemic medication' in our algorithm minimizes the misclassification of T2D with early use of insulin, as T1D. Moreover, the 'Started taking insulin within a year after the diagnosis' criterion would exclude the patients with T2D with later use of insulin from T1D ascertainment. The equivalent of our algorithm for the NHIS would be 'No use of oral hypoglycemic medication', 'Current insulin use', and 'Continuous use of insulin'.

The self-report of T1D added to the NHIS in 2016–2017, and applied by Casagrande's algorithms 4, 5, and 6, does not match with 'Current insulin use' and 'Continuous use of insulin' consistently enough to help improve the ascertainment of T1D. As the article reported, among persons who self-reported T1D, about one-third reported taking no insulin, and only around one-third reported continuous insulin use.¹ Algorithms 2, 3, and 7 used age at diabetes onset and consequently excluded about 40% of T1D from T1D ascertainment. Algorithm 1 applied 'Current insulin use' and 'Continuous use of insulin', but misses 'No use of oral hypoglycemic medication', which means it would misclassify T2D cases with early use of insulin as T1D. Since the majority of total diabetes cases are T2D (90%–95%), and studies like the Outcome



► <http://dx.doi.org/10.1136/bmjdr-2020-001917>



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, Irvine, California, USA

Correspondence to
Ms Mitra Mosslemi;
mosslemm@uci.edu

Reduction with Initial Gargine Intervention trial support early initiation of insulin therapy in patients with T2D,¹⁰ misclassifying T2D cases with the early use of insulin as T1D would be a bigger misclassification in T1D ascertainment than potentially missing less than 5% of patients with T1D who took oral hypoglycemic medications.

Consequently, our treatment-based algorithm improves the accuracy of ascertaining T1D cases in the US health registries compared with the discussed algorithms. We strongly support the call for future research linking survey questions to medical records and providing additional information on which algorithms perform best for classifying T1D using survey data, and again thank Casagrande and colleagues for their valuable work in this area.

Acknowledgements The authors would like to acknowledge the researchers, staff, and participants of the NHANES, NHIS, UK Biobank, SEARCH, and T1D Exchange research networks.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests NDW receives research support through his institution not related to this study from Boehringer Ingelheim and Novo Nordisk and is a consultant for AstraZeneca.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Mitra Mosslemi <http://orcid.org/0000-0002-1091-547X>

REFERENCES

- 1 Casagrande SS, Lessem SE, Orchard TJ, *et al*. Comparison of several survey-based algorithms to ascertain type 1 diabetes among US adults with self-reported diabetes. *BMJ Open Diabetes Res Care* 2020;8:e001917.
- 2 Mosslemi M, Park HL, McLaren CE, *et al*. A treatment-based algorithm for identification of diabetes type in the National health and nutrition examination survey. *Cardiovasc Endocrinol Metab* 2020;9:9–16.
- 3 Thomas NJ, Jones SE, Weedon MN, *et al*. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. *Lancet Diabetes Endocrinol* 2018;6:122–9.
- 4 Mayer-Davis EJ, Lawrence JM, Dabelea D, *et al*. Incidence trends of type 1 and type 2 diabetes among Youths, 2002–2012. *N Engl J Med* 2017;376:1419–29.
- 5 Gourgari E, Wilhelm EE, Hassanzadeh H, *et al*. A comprehensive review of the FDA-approved labels of diabetes drugs: indications, safety, and emerging cardiovascular safety data. *J Diabetes Complications* 2017;31:1719–27.
- 6 Foster NC, Beck RW, Miller KM, *et al*. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. *Diabetes Technol Ther* 2019;21:66–72.
- 7 Selvin E, Parrinello CM, Daya N, *et al*. Trends in insulin use and diabetes control in the U.S.: 1988–1994 and 1999–2012. *Diabetes Care* 2016;39:e33–5.
- 8 Centers for disease control and prevention. National diabetes statistics report, 2020. Atlanta, GA: centers for disease control and prevention, U.S. dept of health and human services; 2020.. Available: <https://www.cdc.gov/diabetes/data/statistics-report/index.html> [Accessed 16 Feb 2021].
- 9 American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Medical Care in Diabetes-2020*. *Diabetes Care* 2020;43:S98–110.
- 10 ORIGIN trial investigators, Gilbert RE, Mann JFE, *et al*. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the outcome reduction with an initial glargine intervention (origin) trial. *Diabetologia* 2014;57:1325–31.